ByAdam Feuerstein,Elaine Chen, andAllison DeAngelis
Oct. 1, 2026
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcastThe Readout Loudand author of the newsletterAdam’s Biotech Scorecard.You can reach Adam on Signal at stataf.54.
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writesThe Readout newsletter, and co-hosts STAT’s weekly biotech podcast,The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.
Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis.01.
On this week’s episode of “The Readout LOUD”: Why have so many Americans lost trust in science? And how have our policy leaders fueled that mistrust? We speak to STAT’s newtrust-in-science reporter Nicholas Florkoabout the impact of Americans’ growing skepticism of science.
Your co-hosts also chat about a clinical update from UniQure on itsgene therapy for Huntington’s disease, ajuicy lawsuitfiled by the gene-editing company Beam Therapeutics against a Chinese competitor, and a shift in the way pharma companies like Novo and Eli Lilly aretalking about their GLP-1 products.
Advertisement
Be sure to sign up for “The Readout LOUD” onApple Podcasts,Spotify, or wherever you get your podcasts.
biotechnology,
China,
Eli Lilly,
gene editing,
Novo Nordisk,
Obesity,
PharmaceuticalsSubmit a correction requestReprintsSenior Writer, Biotech
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcastThe Readout Loudand author of the newsletterAdam’s Biotech Scorecard.You can reach Adam on Signal at stataf.54.
National Biotech Reporter
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writesThe Readout newsletter, and co-hosts STAT’s weekly biotech podcast,The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.
Biotech Startups and Venture Capital Reporter
Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis.01.
Newsletter
Your morning rundown of the science, politics, and money driving biotech today
